Both in Pharmaceuticals
Zenas BioPharma vs Ocular Therapeutix
Over the past year ZBIO returned +30.1% and OCUL returned −37.2%; their daily moves had a correlation of 0.15.
ZBIO +30.1% OCUL −37.2%Growth of $1, one year, split-adjusted
| Metric | ZBIO | OCUL |
|---|---|---|
| Price | $26.76 | $7.87 |
| Market cap | $1.74B | $1.73B |
| Today | −2.87% | +2.81% |
| 1 month | −14.4% | −24.0% |
| 6 months | +46.8% | +6.4% |
| Year to date | −26.3% | −35.2% |
| 1 year | +33.2% | −37.2% |
| Revenue growth (YoY) | — | +0.1% |
| Gross margin | 100.0% | 85.1% |
| Net margin | −11145.6% | −584.5% |
| P/E (TTM) | — | — |
| Price / sales | 1,744.1× | 33.2× |
| Net cash | $346.1M | $525.8M |
| Dividend yield | — | — |
| Volatility (60d) | 54.4% | 71.7% |
| Short % of float | 38.1% | 15.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).